Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open, randomised, parallel-group study evaluating the exposure of and safety of O304 Na-salt and in combination with dapagliflozin (Forxiga) in healthy volunteers

Next Previous
Trial Profile

An open, randomised, parallel-group study evaluating the exposure of and safety of O304 Na-salt and in combination with dapagliflozin (Forxiga) in healthy volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATX 304 (Primary) ; Dapagliflozin (Primary)
  • Indications Metabolic disorders; Renal failure; Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Betagenon

Most Recent Events

  • 20 Aug 2020 New trial record
  • 17 Aug 2020 According to a Betagenon media release, Status changed from planning to recruiting.
  • 17 Aug 2020 According to a Betagenon media release, approvals from the Medicine Product Agency, Sweden, and the Ethics committee to conduct the clinical study have recently been granted.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top